- Personalized Patient Regimen Calendar
- Compendium of Drug Regimens
- Diagnosis, Staging, Prognosis and Response Guide
- Clinical Commentaries
- Diagnosis/Staging
- Risk Assessment
- Response Assessment
- Treatment Goals
- Monitoring
- Eldery Patients
- Induction Therapy
- Stem Cell Transplant
- Relapsed/Refractory
- VTE Risk Reduction
- PN Risk Reduction
- Bone Disease
- Clinical Trials
- FAQ Library
- General Education
- Is there a role for multidisciplinary care in the treatment of multiple myeloma?
- What future advances can be expected in myeloma therapy?
- Expediting MM patient care
- New directions in multiple myeloma
- Clinician and patient frustrations dealing with incurable disease
- Navigating patient misinformation from the internet
- Diagnosis/Staging
- Prognostic Assessment
- Response Assessment
- Treatment Goals
- Test/Monitoring
- Patient Communication
- Treating Elderly
- Induction Therapy
- Stem Cell Transplant
- Maintenance Therapy
- Comorbidities/SEs
- Side Effects of Emerging Therapies
- How should infection be prevented and managed in the multiple myeloma patient?
- How do I manage bone disease in my myeloma patients?
- How do we manage pain in myeloma patients?
- How do I manage anemia in myeloma patients?
- How can we prevent infections in myeloma patients?
- How can we reduce bone complications in myeloma patients?
- Can renal failure be reversed in multiple myeloma patients?
- Bisphosphonate administration
- When is it appropriate to use IVIGs in multiple myeloma?
- How do I reduce the risk of renal complications?
- Osteonecrosis of the jaw
- Screening for myeloma side effects
- Managing spine compression fractures
- Bone Disease
- Clinical Trials
- Emerging Therapeutics
- Nurses & Pharmacists
- Risk Assessment
- Comorbidities/SEs
- Bone Disease
- VTE Risk Reduction
- Pharmacist
- ONS Highlights
- Nurse FAQs
- Diagnosis/Treatment
- Staging
- Risk Assess/Prognosis
- Transplant
- Maintenance Therapy
- Comorbidities/SEs
- Renal Impairment
- Bone Disease
- PN
- Patient Communication
- Induction Therapy
- Treating the Elderly
NEW! Myeloma Treatment Resource®Emerging Therapeutics Practice SurveyWhat's New
|
In the News
- NEWS FLASH UK: NHS: Two new multiple myeloma treatments -- NICE draft guidance recommends bortezomib and thalidomide for multiple myeloma - 2010-08-26
- CELG: Patent Challenge To Lenalidomide (Revlimid) Could Shorten Exclusivity Period From 2026 To 2019 - 2010-08-25
- Celgene expects patent challenge to Lenalidomide-Bloomburg Business Week - 2010-08-25
- Managing Myeloma News Flash: Myeloma Responds to Less-Intense Therapy in Elderly- Lancet Oncology Online - 2010-08-24
